Stay updated with breaking news from Tar 210. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
TAR-210 was safe and showed promising clinical activity in patients with FGFR-altered high- and intermediate-risk non–muscle-invasive bladder cancer.
Roger Li, MD, discusses the rationale of the phase 3 MoonRISe-1 trial (NCT06319820).
Siamak Daneshmand, MD, discusses the results of SunRISe-1 study of TAR-200, an intravesical drug delivery system, in patients with BCG-unresponsive HR NMIBC from ESMO 2023.
Antoni Vilaseca, MD, PhD, explains the unique mechanism of the TAR-210 erdafitinib delivery system and expands on the key objectives, trial design, and patient characteristics of a phase 1 trial evaluating TAR-210 in patients with recurrent NMIBC or MIBC harboring select FGFR mutations or fusions.